Thiamphenicol

證據等級: L5

預測適應症: 10 個

Thiamphenicol: From Broad-Spectrum Antibacterial Therapy to Interventricular Septum Aneurysm

One-Sentence Summary

Thiamphenicol is a broad-spectrum antibacterial (a chloramphenicol analogue that inhibits bacterial 50S ribosomal protein synthesis); no approved-indication text or detailed mechanism-of-action data is currently on file for this evaluation. The TxGNN model predicts it may be relevant to Interventricular Septum Aneurysm, but this prediction is currently supported by 0 clinical trials and 0 publications. Evidence strength is at the model-prediction-only level (L5), and the drug is not currently marketed in Denmark.

Quick Overview

Item	Content
Original Indication	Not available — no approved-indication text on file (drug class: broad-spectrum antibacterial)
Predicted New Indication	Interventricular Septum Aneurysm
TxGNN Prediction Score	96.54%
Evidence Level	L5
Denmark Market Status	Not Marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for thiamphenicol in this evidence pack. Based on known pharmacological class information, thiamphenicol is a broad-spectrum antibacterial (a chloramphenicol analogue) that acts by inhibiting bacterial 50S ribosomal subunit protein synthesis. No original approved indication is recorded in this evidence pack, so a direct comparison between an established indication and the predicted new indication cannot be made.

Interventricular septum aneurysm is a structural/congenital cardiac abnormality, not a condition primarily driven by infectious or inflammatory processes. There is no known biological pathway connecting ribosomal protein synthesis inhibition to septal wall structure, cardiac fibrosis, or cardiac developmental signalling. The TxGNN model’s high score (96.54%) most likely reflects an indirect association captured at the knowledge-graph embedding level (e.g., shared drug–gene–disease co-occurrence patterns) rather than a mechanism-driven signal.

Notably, several other top-ranked TxGNN predictions for this drug (pulmonary valve disease, orofacial clefting syndrome, Laubry-Pezzi syndrome, Pierre Robin syndrome) share the same pattern — structural or developmental conditions with no plausible mechanistic link to an antibacterial agent, and no corroborating trial or literature evidence. This consistent absence of independent support across the top prediction set further limits confidence in this specific candidate.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Denmark Market Information

No marketing authorisations are currently recorded for thiamphenicol in Denmark (market status: Not Marketed; total authorisations: 0).

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate rests on evidence level L5 (model prediction only) with no supporting clinical trials or literature, and the proposed mechanistic link between an antibacterial agent and a structural cardiac abnormality is not biologically plausible based on currently available information. In addition, a Blocking data gap (missing TFDA/SmPC label warnings and contraindications) prevents even an initial safety (S1) assessment.

To proceed, the following is needed:

Confirmed mechanism of action (MOA) data for thiamphenicol
Official product label / SmPC warnings, contraindications, and drug interaction data
Preclinical or mechanistic studies establishing a plausible link to interventricular septum aneurysm (or reprioritisation toward a mechanistically supported indication)
Independent clinical trial or literature evidence before advancing beyond S0
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.